Yang, L. and Ma, A. 2023. Cost-utilities Analysis of Polatuzumab Vedotin Combined with Bendamustine and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation. Frontiers in Business, Economics and Management. 8, 3 (Apr. 2023), 178–184. DOI:https://doi.org/10.54097/fbem.v8i3.7835.